Bone Marrow-Derived Endothelial Progenitors Expressing Delta-Like 4 (Dll4) Regulate Tumor Angiogenesis
暂无分享,去创建一个
C. Real | H. Yagita | P. Pinto-do-Ó | Francisco Caiado | S. Dias | Leonor Remédio | Cátia Igreja | A. Duarte | A. Trindade | C. Borges | Carla Real | Cristina Borges
[1] E. Pasquier,et al. Endothelial progenitor cells: hope beyond controversy. , 2010, Current cancer drug targets.
[2] R. Oumedaly,et al. Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia , 2010 .
[3] M. Klagsbrun,et al. Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. , 2010, Blood.
[4] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[5] C. Real,et al. Notch Pathway Modulation on Bone Marrow-Derived Vascular Precursor Cells Regulates Their Angiogenic and Wound Healing Potential , 2008, PloS one.
[6] J. Becker,et al. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. , 2008, Blood.
[7] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[8] B. Engelhardt,et al. Inducible endothelial cell-specific gene expression in transgenic mouse embryos and adult mice. , 2008, Experimental cell research.
[9] H. Verheul,et al. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.
[10] Adam L. Bermange,et al. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis , 2007, Development.
[11] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[12] Minhong Yan,et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.
[13] Gavin Thurston,et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.
[14] R. Motzer,et al. Targeted therapy for metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Harris,et al. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. , 2006, Blood.
[16] Adrian L Harris,et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. , 2005, Cancer research.
[17] A. Karsan,et al. Minimal Contribution of Marrow-Derived Endothelial Precursors to Tumor Vasculature1 , 2005, The Journal of Immunology.
[18] A. Ridley,et al. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. , 2005, Blood.
[19] B. Peters,et al. Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.
[20] Gavin Thurston,et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] Thomas Hartmann,et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.
[22] Janet Rossant,et al. Dosage-sensitive requirement for mouse Dll4 in artery development. , 2004, Genes & development.
[23] J. Isner,et al. Stromal Cell–Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell Recruitment for Ischemic Neovascularization , 2003, Circulation.
[24] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[25] R Bicknell,et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. , 2001, Differentiation; research in biological diversity.
[26] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[27] S. Rafii,et al. Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector‐Mediated Elevation of Serum Levels of SDF‐1, VEGF, and Angiopoietin‐1 , 2001, Annals of the New York Academy of Sciences.
[28] J. Rossant,et al. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[29] F. Balkwill,et al. Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model , 2000, British Journal of Cancer.
[30] J. Sundberg,et al. Notch signaling is essential for vascular morphogenesis in mice. , 2000, Genes & development.
[31] J. Isner,et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.
[32] F. Balkwill,et al. Multiple molecular and cellular changes associated with tumour stasis and regression during IL‐12 therapy of a murine breast cancer model , 1998, International journal of cancer.
[33] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.